Skip to main content

Annual General Meeting in ALK-Abelló A/S held on 16 March 2022

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 16 March 2022.

The Annual General Meeting transacted the following business:

  • Adoption of the annual report 2021 and discharge of the Board of Directors and Board of Management
  • No declaration of ordinary dividend in accordance with the approved annual report for 2021
  • Adoption of the remuneration report for 2021
  • Adoption of the remuneration to the Board of Directors for the present year
  • Re-election of Anders Hedegaard as the Chairman of the Board of Directors
  • Re-election of Lene Skole as the Vice Chairman of the Board of Directors
  • Re-election of Gitte Aabo, Lars Holmqvist, Bertil Lindmark and Jakob Riis as well as new election of Alan Main to the Board of Directors
  • Re-appointment of PwC Statsautoriseret Revisionspartnerselskab as the company’s auditor
  • Adoption of the following proposals from the Board of Directors:

       (a) Renewal of the Board’s powers to increase the share capital (article 4a of the Articles of Association)

       (b) Amendment of the denomination of shares

       (c) Amendment of article 6.4 of the Articles of Association

       (d) Authorisation to the chairman of the meeting

ALK-Abelló A/S

For further information please contact:

Anders Hedegaard, Chairman, tel. +45 4574 7576

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.